NCT00951028

Brief Summary

This study will test a therapy for both helping people adhere to their HIV medication regimens and treating them for depression.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P50-P75 for not_applicable hiv

Timeline
Completed

Started Sep 2008

Longer than P75 for not_applicable hiv

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

August 3, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 4, 2009

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
Last Updated

June 18, 2013

Status Verified

June 1, 2013

Enrollment Period

4.6 years

First QC Date

August 3, 2009

Last Update Submit

June 17, 2013

Conditions

Keywords

Adherence

Outcome Measures

Primary Outcomes (1)

  • changes in HIV medication adherence, as measured by electronic medication event monitoring system (MEMS) pill-cap scores

    HIV medication adherence is assessed more frequently during the acute study period (baseline to post-treatment), and then at the follow up major visits.

    Measured at each visit - baseline, interim visits, and after 4, 8, and 12 months

Secondary Outcomes (5)

  • changes in Severity of depression, as assessed on the Montgomery-Asberg Depression Rating Scale (MADRS) by a blinded independent assessor

    Measured at baseline and after 4, 8, and 12 months

  • changes in depression, as measured by the blinded assessor CGI rating

    Measured at baseline and after 4, 8, and 12 months

  • changes in RNA viral load

    Measured at baseline and after 4, 8, and 12 months

  • changes in CD4 cell count

    Measured at baseline and after 4, 8, and 12 months

  • changes in self-reported depression (CESD)

    Measured at each visit

Study Arms (3)

Enhanced treatment as usual

ACTIVE COMPARATOR

Participants will receive the life-steps intervention and treatment as usual.

Behavioral: Life-steps adherence treatment

CBT for adherence and depression (CBT-AD)

EXPERIMENTAL

Participants will receive the life-steps and CBT-AD interventions.

Behavioral: Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)Behavioral: Life-steps adherence treatment

ISP for adherence and depression (ISP-AD)

ACTIVE COMPARATOR

Participants will receive the life-steps and ISP-AD interventions.

Behavioral: Life-steps adherence treatmentBehavioral: Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)

Interventions

12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications

CBT for adherence and depression (CBT-AD)

Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management

CBT for adherence and depression (CBT-AD)Enhanced treatment as usualISP for adherence and depression (ISP-AD)

12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.

ISP for adherence and depression (ISP-AD)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HIV-infected
  • Current diagnosis of depression or prescribed an antidepressant medication with at least some residual symptoms (e.g., clinical global impressions \[CGI\] scale score of 2 or greater)
  • Prescribed a stable regimen of highly active antiretroviral therapy (HAART) for HIV for at least 2 months

You may not qualify if:

  • Active, untreated, and unstable major mental illness (i.e., untreated psychosis or mania) that would interfere with cognitive behavioral therapy (CBT) treatment for depression
  • Diagnosis with any primary psychotic disorder, even if treated
  • Treatment with CBT within the past year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Fenway Community Health Center

Boston, Massachusetts, 02215, United States

Location

Butler Hospital

Providence, Rhode Island, 02906, United States

Location

The Miriam Hospital

Providence, Rhode Island, 02906, United States

Location

MeSH Terms

Conditions

DepressionHIV Infections

Interventions

Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Steven A. Safren, PhD

    Partners HealthCare

    PRINCIPAL INVESTIGATOR
  • C. Andres Bedoya, PhD

    Partners HealthCare

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Behavioral Medicine

Study Record Dates

First Submitted

August 3, 2009

First Posted

August 4, 2009

Study Start

September 1, 2008

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

June 18, 2013

Record last verified: 2013-06

Locations